A strategy with an optional second step also runs the risk of situations such as missed carriers of non-founder pathogenic variants in BRCA1/2 or other HBOC-related genes in individuals who did not meet the criteria for further genetic analysis or in whom no further testing was performed because of dropout or cancer-related death. This evidence concerns the gene BRCA1 and cancer.